KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Cash & Equivalents (2017 - 2025)

Novartis Ag's Cash & Equivalents history spans 9 years, with the latest figure at $11.6 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 348.36% year-over-year to $11.6 billion; the TTM value through Dec 2025 reached $11.6 billion, up 348.36%, while the annual FY2025 figure was $11.6 billion, 348.36% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $11.6 billion at Novartis Ag, up from $2.6 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $13.4 billion in Q4 2023 and bottomed at $2.6 billion in Q4 2024.
  • The 5-year median for Cash & Equivalents is $11.6 billion (2025), against an average of $9.5 billion.
  • The largest annual shift saw Cash & Equivalents crashed 80.7% in 2024 before it surged 348.36% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $12.4 billion in 2021, then plummeted by 39.41% to $7.5 billion in 2022, then soared by 78.17% to $13.4 billion in 2023, then plummeted by 80.7% to $2.6 billion in 2024, then soared by 348.36% to $11.6 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Cash & Equivalents are $11.6 billion (Q4 2025), $2.6 billion (Q4 2024), and $13.4 billion (Q4 2023).